Biogen (BIIB): nusinersen Is In the Stock - Leerink

October 12, 2016 7:17 AM EDT
Get Alerts BIIB Hot Sheet
Price: $290.65 -3.01%

Rating Summary:
    17 Buy, 16 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade BIIB Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst, Geoffrey Porges, reiterated his Market Perform rating on shares of Biogen (NASDAQ: BIIB) following Biogen’s disclosure of positive pivotal and phase II trial data for spinal muscular atrophy (SMA) treatment with nusinersen.

The analyst believes that most of the value of nusinersen is already reflected in Biogen’s stock price. However, there could be another $8-$9 on approval, presuming regulators grant the company the broad label they are seeking.

No change to the price target of $367.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $298.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment